Tekla Life Sciences Stock Net Income
| HQL Stock | USD 17.04 0.25 1.45% |
As of the 28th of January, Tekla Life has the Semi Deviation of 1.3, coefficient of variation of 1058.93, and Risk Adjusted Performance of 0.0746. Tekla Life technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Tekla Life Sciences downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Tekla Life is priced more or less accurately, providing market reflects its prevalent price of 17.04 per share. Given that Tekla Life Sciences has jensen alpha of 0.0793, we advise you to double-check Tekla Life Sciences's current market performance to make sure the company can sustain itself at a future point.
Tekla Life Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.9173 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 98.4 M | 103.4 M | |
| Net Income From Continuing Ops | 98.4 M | 103.4 M | |
| Net Loss | -94.1 M | -89.4 M | |
| Net Income Per Share | 2.67 | 2.80 | |
| Net Income Per E B T | 0.90 | 0.80 |
Tekla | Net Income | Build AI portfolio with Tekla Stock |
Latest Tekla Life's Net Income Growth Pattern
Below is the plot of the Net Income of Tekla Life Sciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tekla Life Sciences financial statement analysis. It represents the amount of money remaining after all of Tekla Life Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tekla Life's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 85.59 M | 10 Years Trend |
|
Net Income |
| Timeline |
Tekla Net Income Regression Statistics
| Arithmetic Mean | 47,452,730 | |
| Coefficient Of Variation | 130.49 | |
| Mean Deviation | 47,745,206 | |
| Median | 68,555,677 | |
| Standard Deviation | 61,921,030 | |
| Sample Variance | 3834.2T | |
| Range | 227.7M | |
| R-Value | 0.10 | |
| Mean Square Error | 4045.7T | |
| R-Squared | 0.01 | |
| Significance | 0.69 | |
| Slope | 1,273,271 | |
| Total Sum of Squares | 61347.4T |
Tekla Net Income History
Other Fundumenentals of Tekla Life Sciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tekla Life Net Income component correlations
Tekla Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tekla Life is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Net Income. Since Tekla Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth (0.70) |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tekla Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tekla Life's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tekla Life.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Tekla Life on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Tekla Life Sciences or generate 0.0% return on investment in Tekla Life over 90 days. Tekla Life is related to or competes with Cion Investment, BlackRock TCP, Gladstone Capital, GigCapital7 Corp, Eagle Point, PennantPark Investment, and Source Capital. Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC More
Tekla Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tekla Life's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tekla Life Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.45 | |||
| Information Ratio | 0.0418 | |||
| Maximum Drawdown | 6.78 | |||
| Value At Risk | (2.15) | |||
| Potential Upside | 2.88 |
Tekla Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tekla Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tekla Life's standard deviation. In reality, there are many statistical measures that can use Tekla Life historical prices to predict the future Tekla Life's volatility.| Risk Adjusted Performance | 0.0746 | |||
| Jensen Alpha | 0.0793 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0434 | |||
| Treynor Ratio | 0.1735 |
Tekla Life January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0746 | |||
| Market Risk Adjusted Performance | 0.1835 | |||
| Mean Deviation | 1.17 | |||
| Semi Deviation | 1.3 | |||
| Downside Deviation | 1.45 | |||
| Coefficient Of Variation | 1058.93 | |||
| Standard Deviation | 1.5 | |||
| Variance | 2.26 | |||
| Information Ratio | 0.0418 | |||
| Jensen Alpha | 0.0793 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0434 | |||
| Treynor Ratio | 0.1735 | |||
| Maximum Drawdown | 6.78 | |||
| Value At Risk | (2.15) | |||
| Potential Upside | 2.88 | |||
| Downside Variance | 2.09 | |||
| Semi Variance | 1.69 | |||
| Expected Short fall | (1.24) | |||
| Skewness | 0.1491 | |||
| Kurtosis | 0.2633 |
Tekla Life Sciences Backtested Returns
As of now, Tekla Stock is very steady. Tekla Life Sciences owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Tekla Life Sciences, which you can use to evaluate the volatility of the company. Please validate Tekla Life's Risk Adjusted Performance of 0.0746, semi deviation of 1.3, and Coefficient Of Variation of 1058.93 to confirm if the risk estimate we provide is consistent with the expected return of 0.0095%. The entity has a beta of 0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tekla Life's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tekla Life is expected to be smaller as well. Tekla Life Sciences right now has a risk of 1.46%. Please validate Tekla Life downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Tekla Life will be following its existing price patterns.
Auto-correlation | -0.23 |
Weak reverse predictability
Tekla Life Sciences has weak reverse predictability. Overlapping area represents the amount of predictability between Tekla Life time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tekla Life Sciences price movement. The serial correlation of -0.23 indicates that over 23.0% of current Tekla Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.23 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tekla Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tekla Life Sciences reported net income of 85.59 M. This is 93.3% lower than that of the Capital Markets sector and 68.58% lower than that of the Financials industry. The net income for all United States stocks is 85.01% higher than that of the company.
Tekla Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tekla Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tekla Life could also be used in its relative valuation, which is a method of valuing Tekla Life by comparing valuation metrics of similar companies.Tekla Life is currently under evaluation in net income category among its peers.
Tekla Life Current Valuation Drivers
We derive many important indicators used in calculating different scores of Tekla Life from analyzing Tekla Life's financial statements. These drivers represent accounts that assess Tekla Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Tekla Life's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 350.8M | 352.8M | 423.2M | 447.8M | 403.0M | 273.3M | |
| Enterprise Value | 361.9M | 352.8M | 423.2M | 447.7M | 403.0M | 274.1M |
Tekla Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Life's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Tekla Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | -0.0043 | ||||
| Profit Margin | 44.16 % | ||||
| Operating Margin | (3.47) % | ||||
| Current Valuation | 511.69 M | ||||
| Shares Outstanding | 29.6 M | ||||
| Shares Owned By Institutions | 29.34 % | ||||
| Number Of Shares Shorted | 56.66 K | ||||
| Price To Earning | 2.84 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 264.01 X | ||||
| Revenue | 86.39 M | ||||
| Gross Profit | 1.94 M | ||||
| EBITDA | 85.59 M | ||||
| Net Income | 85.59 M | ||||
| Cash And Equivalents | 292.4 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 1.73 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 17.35 X | ||||
| Cash Flow From Operations | 31.71 M | ||||
| Short Ratio | 0.38 X | ||||
| Earnings Per Share | 2.79 X | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 511.76 M | ||||
| Total Asset | 515.38 M | ||||
| Retained Earnings | 77.6 M | ||||
| Annual Yield | 0.11 % | ||||
| Five Year Return | 8.83 % | ||||
| Net Asset | 515.38 M | ||||
| Last Dividend Paid | 1.82 |
About Tekla Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Tekla Life Piotroski F Score and Tekla Life Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth (0.70) |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.